In focussed cities B2C revenues have grown to Rs 131 cr registering growth of 17 per cent on YoY basis
Metropolis Healthcare recently announced its un-audited consolidated financial results for the quarter ended September 30, 2019.
Key Highlights H1FY20
- Overall revenue from B2C stood at 44.4 per cent in H1FY20 as compared to 43.6 per cent in H1FY19.
- In focussed cities B2C revenues have grown to Rs 131 cr registering a growth of 17 per cent on YoY basis. B2C share in focussed cities was higher at 56 per cent as compared to 52 per cent in H1FY19.
- Acquisition of four front end labs in Surat has helped us expand our market share in this focus city.
- Our Delhi Regional Reference Lab has been relocated and expanded to 15,000 sq ft from 8,000 sq ft earlier which allows us for test menu expansion, faster turn around time.
- A total of 14 new tests (in areas of Genomics, Onco-pathology, new-born screening and transplant pathology) have been validated and added to the test menu in H1FY20 thus expanding our capabilities to do more specialis ed tests.
- A few technology and digital initiatives have gone live in H1FY20 that enables better control, data security, business continuity, business revenue generation capabilities, improved operational efficiency, efficiencies in productivity and an improved customer experience.